本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"或"蓝帆医疗"）第六届董事会第十六 次会议于 2024 年 12 月 2 日以电子邮件的方式发出通知，于 2024 年 12 月 6 日在公司 第二会议室以现场及通讯表决相结合的方式召开。本次会议应参加会议董事 7 人，实 际参加会议董事 7 人；刘文静女士、钟舒乔先生、刘海波先生以现场的方式出席会议， 李振平先生、于苏华先生、赵永清先生和乔贵涛先生以通讯的方式出席会议。公司董事 长刘文静女士主持了本次会议。会议的通知、召开、表决程序符合《中华人民共和国公 司法》和《蓝帆医疗股份有限公司章程》（以下简称"《公司章程》"）的规定。 二、董事会会议审议情况 1、逐项审议并通过了《关于2025年度日常关联交易预计的议案》； | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-098 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 第六届董事会第十六次会议决议 ...

关于 2025 年度购买理财产品的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 重要内容提示： 1、投资种类：安全性高、流动性好的金融机构理财产品。 2、投资金额及期限：根据日常经营资金需求，公司及子公司使用额度不超过 7.4 亿 元的闲置自有资金进行投资理财，即在任一时点用于投资理财的资金余额不超过 7.4 亿 元，在 2 亿元人民币额度内，资金可以循环使用，自本事项经董事会审议通过之日起一 年内有效。 证券代码：002382 证券简称：蓝帆医疗 公告编号：2024-102 债券代码：128108 债券简称：蓝帆转债 蓝帆医疗股份有限公司 3、特别风险提示：虽然理财产品属于风险较低的投资品种且经过严格评估，但金融 市场受宏观经济影响较大，不排除该项投资受到市场波动的影响。 为提高蓝帆医疗股份有限公司（以下简称"公司"）及子公司的资金利用效率和收 益，2025 年度公司及子公司拟使用闲置资金购买理财产品。具体如下： 一、投资情况概述 1、投资目的：在不影响正常生产经营的情况下，使用自有资金购买理财产品，有利 于提高资金使用效率，增加公司收益，在保证资金 ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-100 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于 2025 年度日常关联交易预计的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、日常关联交易基本情况 （一）日常关联交易概述 2025 年度，蓝帆医疗股份有限公司（以下简称"公司"、"本公司"或"蓝帆医疗"） 及子公司拟与关联方开展日常关联交易，具体如下： 1、公司及子公司拟向山东朗晖石油化学股份有限公司及其子公司采购原材料 公司及子公司拟向关联方山东朗晖石油化学股份有限公司（以下简称"朗晖石化"） 及其子公司上海蓝帆实业有限公司（以下简称"蓝帆实业"）合计采购原材料金额不超 过 63,937 万元。 2、公司及子公司拟向淄博宏达热电有限公司及其销售代理机构采购燃料和动力 公司及子公司拟向关联方淄博宏达热电有限公司（以下简称"宏达热电"）及其销 售代理机构采购燃料和动力金额不超过 48,786 万元。 3、公司的子公司北京蓝帆柏盛医疗科技 ...

全体独立董事本着客观公正的立场，就公司第六届董事会第十六次会议相关事项发 表审核意见如下： 关于 2025 年度日常关联交易预计的审核意见 蓝帆医疗股份有限公司 2024 年第二次独立董事专门会议审核意见 根据《上市公司独立董事管理办法》、《深圳证券交易所上市公司自律监管指引第 1号——主板上市公司规范运作》等法律法规及《蓝帆医疗股份有限公司章程》的有关 规定，蓝帆医疗股份有限公司（以下简称"公司"）全体独立董事于2024年12月5日召 开2024年第二次独立董事专门会议，本次会议应参加的独立董事三名，实际参加的独 立董事三名。 （此页无正文，为《蓝帆医疗股份有限公司 2024 年第二次独立董事专门会议审核 意见》签字页） 独立董事签名： 赵永清 乔贵涛 刘海波 二〇二四年十二月五日 我们认为：公司及子公司与关联方开展 2025 年度日常关联交易事项是基于公司的 发展战略和生产经营的需要，交易不会影响公司的独立性，不会对公司的财务状况、经 营成果产生不良影响。关联交易定价政策及依据公允，不存在损害公司及其股东、特别 是中小股东利益的行为。我们同意公司及子公司与关联方开展 2025 年度日常关联交易 事项。 （ ...

本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、监事会会议召开情况 第六届监事会第十二次会议决议公告 蓝帆医疗股份有限公司（以下简称"公司"）第六届监事会第十二次会议于 2024 年 12 月 2 日以电子邮件的方式发出通知，于 2024 年 12 月 6 日在公司总部第二会议 室以现场及通讯表决相结合的方式召开。本次会议应参加监事 3 人，实际参加监事 3 人，周治卫先生和宗秋月女士以现场的方式出席会议，卢凌威先生以通讯的方式出席 会议。卢凌威先生主持了本次会议。会议的召开符合《中华人民共和国公司法》和 《蓝帆医疗股份有限公司章程》的规定。 | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-099 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 1.2 公司及子公司拟向淄博宏达热电有限公司及其销售代理机构采购燃料和动力 公司及子公司拟向关联方淄博宏达热电有限公司及其销售代理机构采购燃料和动 力金额不超过 48,786 万元。 表决结果：同意票 3 票， ...

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-097 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于公司为子公司向银行申请授信提供担保 近日，公司与兴业银行股份有限公司签订了《最高额保证合同》，为全资子公司淄 博蓝帆防护用品有限公司、淄博蓝帆健康科技有限公司分别向兴业银行股份有限公司 申请的人民币 5,000 万元敞口授信提供连带责任担保。 本次担保金额全部发生后未超过公司第六届董事会第五次会议、2023年第一次临 时股东大会审议通过的2024年度公司及子公司申请授信及担保额度的金额范围，无需 另行召开董事会或股东大会审议。 的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 一、担保情况概述 蓝帆医疗股份有限公司（以下简称"公司"）于2023年12月8日召开了第六届董事 会第五次会议、2023年12月26日召开了2023年第一次临时股东大会，审议并通过了《关 于2024年度公司及子公司申请授信及担保额度预计的议案》，公司及子公司2024年 ...

Investment Rating - The report does not explicitly state an investment rating for the company Core Insights - The strategic partnership between 蓝帆医疗 and 万华化学 aims to enhance innovation and market share in the disposable polyurethane glove sector, leveraging each company's strengths for mutual benefit [2][13][14] - The new disposable polyurethane gloves exhibit significant performance advantages over traditional nitrile gloves, including better breathability, skin-friendliness, and overall safety, making them suitable for long-term use in medical settings [2][21] - The company is at a turning point in its performance, with disposable polyurethane gloves expected to become a new growth driver, as evidenced by a 41.74% year-on-year revenue increase in the health protection segment [2][24][28] Summary by Sections Company Overview - 蓝帆医疗 specializes in disposable gloves and cardiovascular medical devices, with a strong market presence in PVC and nitrile gloves, holding approximately 24% and over 21% of the respective export markets [13][14] Strategic Partnership - The collaboration with 万华化学 focuses on deepening cooperation in the medical device sector, particularly in disposable polyurethane gloves and other medical instruments, supported by a joint innovation laboratory [14] Product Performance - Disposable polyurethane gloves are made from water-based polyurethane, offering advantages such as high puncture resistance, elasticity, and hypoallergenic properties, which are superior to PVC and nitrile gloves [18][21] - The gloves are expected to fill market gaps and cater to high-end manufacturing and medical fields, potentially transforming the disposable glove industry [21][23] Market Outlook - The disposable glove industry is recovering, with a projected increase in demand driven by rising consumption levels in developing countries and a lack of competition in the polyurethane glove segment [23] - The company anticipates achieving cost reductions and scaling production by 2025, further enhancing market prospects [23] Financial Performance - In the first three quarters of the year, the company reported a revenue of 46.54 billion yuan, a year-on-year increase of 29.85%, with a notable recovery in gross margins [24][28]

| 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-096 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 蓝帆医疗股份有限公司 关于暂不向下修正"蓝帆转债"转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、截至 2024 年 10 月 29 日，蓝帆医疗股份有限公司（以下简称"公司"）股价 已出现连续三十个交易日中至少有十五个交易日的收盘价低于当期转股价格 85%的情 形，已触发"蓝帆转债"转股价格向下修正条件。 （四）可转债转股价格调整情况 1、公司于 2021 年 5 月 17 日召开第五届董事会第十五次会议，于 2021 年 6 月 8 日召开2020年年度股东大会，审议通过了《关于重大资产重组标的业绩补偿方案的议 案》以及《关于提请股东大会授权公司董事会全权办理重大资产重组标的业绩补偿后 续事项的议案》，同意公司分别以 1 元总价回购注销业绩承诺方淄博蓝帆投资有限公 司持有的公司 23,361,227 股股份、业绩承诺方北京信聿投资中心（有限 ...

Financial Performance - The company's operating revenue for Q3 2024 reached approximately ¥4.65 billion, representing a year-on-year increase of 24.68% and a year-to-date increase of 29.85%[3]. - The net profit attributable to shareholders for Q3 2024 was approximately -¥219.82 million, a decrease of 49.92% year-on-year, with a year-to-date decrease of 38.19%[3]. - The cardiovascular division achieved sales revenue of approximately ¥849 million in the first nine months of 2024, with a year-on-year growth of over 12%[6]. - The health protection division reported a significant turnaround, achieving profitability in the first nine months of 2024, compared to a loss of nearly ¥200 million in the same period last year[7]. - The health protection division's glove product sales volume increased by over 32% year-on-year, contributing to a revenue growth of nearly 40%[8]. - The emergency rescue division generated a profit of nearly ¥22 million in the first nine months of 2024, driven by new marketing strategies and automation efforts[9]. - Total operating revenue for the current period reached ¥4,654,357,096.34, an increase of 30.0% compared to ¥3,584,375,145.17 in the previous period[23]. - Total operating costs increased to ¥4,865,860,745.45, up 21.1% from ¥4,017,539,977.89 in the previous period[23]. - Net profit for the current period was -¥226,923,771.98, an improvement from -¥355,637,784.76 in the previous period[25]. - Operating profit for the current period was -¥228,561,612.09, an improvement from -¥389,517,260.50 in the previous period[24]. - The company recorded a total comprehensive loss of -¥259,903,063.82, compared to -¥233,511,068.67 in the previous period[25]. Cash Flow and Liquidity - The net cash flow from operating activities for the current period was -69,126,761.59 RMB, an increase of 116,742,844.34 RMB compared to the previous period, representing a growth of 62.81%[15]. - The net cash flow from investing activities decreased by 288,619,696.45 RMB to -661,329,077.39 RMB, a decline of 77.44% compared to the previous period[15]. - The net cash flow from financing activities increased significantly by 1,925,118,656.15 RMB to 1,609,508,507.46 RMB, marking a growth of 609.97% compared to the previous period[15]. - The net increase in cash and cash equivalents was 925,648,157.71 RMB, an increase of 1,792,338,237.08 RMB compared to the previous period, representing a growth of 206.80%[15]. - Cash flow from operating activities showed a net outflow of -¥69,126,761.59, an improvement from -¥185,869,605.93 in the previous period[26]. - The total cash inflow from operating activities was ¥4,973,972,064.62, compared to ¥3,876,351,203.29 in the previous period[26]. - The cash and cash equivalents at the end of the period amounted to 2,011,722,908.91 CNY, up from 1,009,150,164.26 CNY year-over-year[27]. - The company’s cash and cash equivalents saw a net increase of 925,648,157.71 CNY, contrasting with a decrease of -866,690,079.37 CNY in the previous year[27]. Assets and Liabilities - The company reported a total asset value of approximately ¥15.63 billion, reflecting an increase of 8.62% compared to the end of the previous year[3]. - As of September 30, 2024, total assets reached CNY 16,980,092,494.85, an increase from CNY 15,633,248,932.86 at the beginning of the period, reflecting a growth of approximately 8.6%[20]. - Current assets totaled CNY 5,436,244,971.41, up from CNY 3,769,548,922.67, indicating a significant increase of about 44.3%[20]. - Total liabilities amounted to CNY 7,010,001,440.03, compared to CNY 6,084,894,349.53 at the beginning of the period, showing an increase of approximately 15.2%[22]. - Long-term borrowings surged by ¥832,014,016.66, a 261.92% increase, due to the renewal of certain bank loans[14]. - Long-term borrowings increased significantly to CNY 1,149,668,221.16 from CNY 317,654,204.50, indicating a growth of approximately 262.5%[22]. - The company's equity attributable to shareholders decreased to CNY 8,835,839,524.12 from CNY 9,548,354,583.33, a decline of about 7.5%[22]. - The company reported a decrease in retained earnings to CNY 1,899,115,173.75 from CNY 2,118,938,016.59, a decline of about 10.4%[22]. Investments and Expenses - The company secured a strategic investment of ¥1 billion from various funds, which will be recognized as financial liabilities due to potential repurchase obligations[10]. - Research and development expenses increased to ¥245,358,824.93, up from ¥227,027,452.75 in the previous period[23]. - Financial expenses rose by ¥57,933,830.84, a 53.89% increase, primarily due to new borrowings and interest expenses from financing confirmations[14]. - Investment income decreased by ¥29,668,310.95, down 135.18%, due to reduced returns from long-term equity investments and financial products[14]. - Other income increased by ¥11,725,435.11, a growth of 166.57%, mainly from the termination of unpayable equity repurchase amounts[14]. - The company reported a significant increase in income tax expenses by ¥41,011,956.33, up 144.36%, due to increased profitability of subsidiaries[14]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 82,059[16]. - The largest shareholder, Zibo Lanfan Investment Co., Ltd., holds 23.31% of the shares, totaling 234,781,123 shares, with 183,300,000 shares pledged[16]. - Shareholder Li Biao holds 2.98% of the shares, totaling 30,003,077 shares[17]. - The company has not disclosed any related party relationships among other shareholders[17]. Strategic Initiatives - The company is actively pursuing strategies for market expansion and new product development, although specific details were not disclosed in the financial report[21]. - The company announced several important matters regarding convertible bonds, including announcements on July 2, August 3, and August 10, 2024[18].

蓝帆医疗股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 | 证券代码：002382 | 证券简称：蓝帆医疗 | 公告编号：2024-094 | | --- | --- | --- | | 债券代码：128108 | 债券简称：蓝帆转债 | | 第六届董事会第十五次会议决议公告 一、董事会会议召开情况 蓝帆医疗股份有限公司（以下简称"公司"）第六届董事会第十五次会议于 2024 年 10 月 25 日以电子邮件的方式发出通知，于 2024 年 10 月 29 日在上海商业总部第一会 议室以现场及通讯表决相结合的方式召开。本次会议应参加会议董事 7 人，实际参加 会议董事 7 人；刘文静女士、钟舒乔先生、赵永清先生以现场的方式出席会议，李振平 先生、于苏华先生、乔贵涛先生、刘海波先生以通讯的方式出席会议。公司董事长刘文 静女士主持了本次会议。会议的通知、召开、表决程序符合《中华人民共和国公司法》 和《蓝帆医疗股份有限公司章程》的规定。 二、董事会会议审议情况 1、审议并通过了《关于<2024年第三季度报告>的议案》； 表决结果：同意票7票，反对票0票 ...